Media headlines about Apollo Endosurgery (NASDAQ:APEN) have been trending somewhat positive on Sunday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.1765342927396 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Apollo Endosurgery (NASDAQ:APEN) opened at $6.40 on Friday. The firm has a market cap of $110.66, a price-to-earnings ratio of -0.17 and a beta of 0.57. Apollo Endosurgery has a 52-week low of $3.55 and a 52-week high of $14.09. The company has a current ratio of 2.54, a quick ratio of 2.00 and a debt-to-equity ratio of 0.58.
A number of equities analysts have issued reports on APEN shares. Northland Securities reaffirmed a “buy” rating on shares of Apollo Endosurgery in a research note on Friday, October 27th. Roth Capital set a $10.00 price objective on shares of Apollo Endosurgery and gave the company a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research raised shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Thursday, November 2nd. Finally, ValuEngine raised shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.44.
In other news, major shareholder Stonepine Capital, L.P. purchased 45,434 shares of Apollo Endosurgery stock in a transaction dated Wednesday, December 20th. The shares were bought at an average cost of $4.50 per share, with a total value of $204,453.00. Following the completion of the transaction, the insider now directly owns 2,410,141 shares in the company, valued at approximately $10,845,634.50. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have bought 263,886 shares of company stock worth $1,288,051. Insiders own 74.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Apollo Endosurgery (APEN) Earns News Impact Rating of 0.12” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/18/apollo-endosurgery-apen-earns-news-impact-rating-of-0-12.html.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.